About
Vironexis was founded in 2021 to translate a groundbreaking discovery — pioneered by our co-founder Timothy Cripe, M.D., Ph.D. and published in Science Advances — into a new therapeutic modality.
We are now a clinical-stage biotechnology company operating the world’s first AAV in vivo protein platform delivering vectorized T-cell engagers in a single IV dose.
Built on the team’s prior experience commercializing AAV gene therapies — including Zolgensma® — TransJoin™ is engineered to outperform CAR-T, bispecific antibodies, and antibody-drug conjugates on each axis that matters: manufacturing complexity, administration logistics, safety, durability, scalability, and patient accessibility.
Our goal: bring durable, T-cell-mediated treatment to a vastly broader population of patients.
Productivity &
Unprecedented Progress
Since our founding in 2021, we have made remarkable progress building our TransJoin™ AAV Gene Therapy Platform and leveraging it to build a pipeline of more than 10 product candidates.
Key Milestones To Date:
INVESTORS
